切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (03) : 114 -117. doi: 10.3877/cma.j.issn.2095-3216.2016.03.005

所属专题: 文献

专家论坛

腹膜透析非感染相关并发症的防治
方炜1,(), 刘曜蓉1   
  1. 1. 200127 上海交通大学医学院附属仁济医院肾脏科,上海市腹膜透析研究中心
  • 收稿日期:2016-04-21 出版日期:2016-06-28
  • 通信作者: 方炜
  • 基金资助:
    上海交通大学医学院高原高峰之双百人计划"研究型医师"项目(20152211); 上海市科委项目(114119a5900)

Prevention and treatment of noninfectious complications in patients under peritoneal dialysis

Wei Fang1,(), Yaorong Liu1   

  1. 1. Department of Nephrology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Research Centre for Peritoneal Dialysis, Shanghai 200127, China
  • Received:2016-04-21 Published:2016-06-28
  • Corresponding author: Wei Fang
  • About author:
    Corresponding author: Fang Wei, Email:
引用本文:

方炜, 刘曜蓉. 腹膜透析非感染相关并发症的防治[J/OL]. 中华肾病研究电子杂志, 2016, 05(03): 114-117.

Wei Fang, Yaorong Liu. Prevention and treatment of noninfectious complications in patients under peritoneal dialysis[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(03): 114-117.

随着腹膜透析的广泛应用及长龄腹膜透析患者的增加,腹膜透析非感染相关并发症的发生日渐增多。腹膜透析非感染相关并发症主要包括导管相关并发症、腹膜透析液留腹引起的腹内压增加相关并发症和代谢并发症等。积极预防和治疗非感染相关并发症是改善腹膜透析患者预后的重要措施之一。

Peritoneal dialysis (PD) has been widely applied for treating patients with end-stage renal disease, and the number of long-term PD patients has continuously increased. Noninfectious complications are emerging as an important cause for technique failure of PD, including catheter-related complications, increased intra-abdominal pressure-related complications, and metabolic complications. Active prevention and treatment of these noninfectious complications are important for improving the outcomes of PD patients.

[1]
Lo WK. Peritoneal dialysis in the Far East-an astonishing situation in 2008[J]. Perit Dail Int, 2009, 29 (Suppl 2): 227-229.
[2]
Cho Y,Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes[J]. Am J Kidney Dis, 2014, 64(2): 278-289.
[3]
Leung CB,Cheung WL,Li PK. Renal registry in Hong Kong-the first 20 years[J]. Kidney Int Suppl, 2015, 5(1): 33-38.
[4]
Schaubel DE,Blake PG,Fenton SSA. Trends in CAPD technique failure: Canada 1981-1997[J]. Perit Dial Int, 2001, 21(4): 365-371.
[5]
Mujais S,Story K. Peritoneal dialysis in the US: Evaluation of outcomes in contemporary cohorts[J]. Kidney Int Suppl, 2006, 103: S21-S26.
[6]
Fang W,Qian J,Lin A, et al. Comparison of peritoneal dialysis practice patterns and outcomes between a Canadian and a Chinese centre[J]. Nephrol Dial Transplant, 2008, 23(12): 4021-4028.
[7]
Liu Y,Zhang L,Lin A, et al. Impact of break-in period on the short-term outcomes of patients started on peritoneal dialysis[J]. Peri Dial Int, 2014, 34(1): 49-56.
[8]
Figueiredo A,Goh BL,Jenkins S, et al. Clinical practice guidelines for peritoneal access[J]. Perit Dial Int, 2010, 30(4): 424-429.
[9]
Gadallah MF,Mignone J,Torres C, et al. The role of peritoneal dialysis catheter configuration in preventing catheter tip migration[J]. Adv Perit Dial, 2000, 16: 47-50.
[10]
Flanigan M,Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments[J]. Perit Dial Int, 2005, 25(2): 132-139.
[11]
Crabtree JH,Burchette RJ,Siddiqi NA. Optimal peritoneal dialysis catheter type and exit site location: an anthropometric analysis[J]. ASAIO J, 2005, 51(6): 743-747.
[12]
Oqünç G,Tuncer M,Oqünç D, et al. Laparoscopic omenal fixation technique versus open surgical placement of peritoneal dialysis catheters[J]. Surg Endosc, 2003, 17(11): 1749-1755.
[13]
Crabtree JH. Development of surgical guidelines for laparoscopic peritoneal dialysis access: down a long and winding road[J]. Perit Dial Int, 2015, 35(3): 241-244.
[14]
Tu WT,Su Z,Shan YS. An original non-traumatic maneuver for repositioning migrated peritoneal dialysis catheters[J]. Perit Dial Int, 2009, 29(3): 325-329.
[15]
Zorzanello MM,Fleming WJ,Prowant BE. Use of tissue plasminogen activator in peritoneal dialysis catheters: A literature review and one center′s experience[J]. Nephrol Nurs J, 2004, 31(5): 534-537.
[16]
王琴,倪兆慧,朱铭力, 等. 腹腔CT影像学检查在腹膜透析相关非感染性腹腔并发症中的诊断价值[J]. 中西医结合学报, 2008, 6(5): 478-481.
[17]
Bargman JM. Complications of peritoneal dialysis related to increased intraabdominal pressure[J]. Kidney Int Suppl, 1993, 40: S75-S80.
[18]
Garcia-Urena MA,Rodriguez CR,Vega Ruiz, et al. Prevalence and management of hernias in peritoneal dialysis patients[J]. Perit Dial Int, 2006, 26(2): 198-202.
[19]
Crabtree JH. Hernia repair without delay in initiation or continuing peritoneal dialysis[J]. Perit Dial Int, 2006, 26(2): 178-182.
[20]
Shah H,Chu M,Bargman JM. Perioperative management of peritoneal dialysis patients undergoing hernia surgery without the use of interim hemodialysis[J]. Perit Dial Int, 2006, 26(6): 684-687.
[21]
Bargman JM. Hernias in peritoneal dialysis patients: limiting occurrence and recurrence[J]. Perit Dial Int, 2008, 28(4): 349-351.
[22]
卞正乾,钟鸣,林爱武, 等. 腹膜透析病人合并腹壁疝的临床诊治体会[J]. 外科理论与实践, 2009, 14(4): 415-419.
[23]
Yoon CY,Lee Mj,Kee YK, et al. Insulin resistance is associated with new-onset cardiovascular events in nondiabetic patients undergoing peritoneal dialysis[J]. Kidney Res Clin Pract, 2014, 33(4): 192-198.
[24]
Cao L,Mou S,Fang W, et al. Hyperleptinaemia, insulin resistance and survival in peritoneal dialysis patients[J]. Nephrology (Carlton), 2015, 20(9): 617-624.
[25]
Selby NM,Fialova J,Burton JO, et al. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid based peritoneal dialysis fluids[J]. Nephrol Dial Transplant, 2007, 22(3): 870-879.
[26]
Bernardo AP,Oliveira JC,Santos O, et al. Insulin resistance in nondiabetic peritoneal dialysis patients: associations with body composition, peritoneal transport, and peritoneal glucose absorption[J]. Clin J Am Soc Nephrol, 2015, 10(12): 2205-2012.
[27]
Szeto CC,Chow KM,Kwan BC, et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis[J]. Am J Kidney Dis, 2007, 49(4): 524-532.
[28]
Oba T,Mori T,Chida M, et al. Glucose and insulin response to Peritoneal dialysis fluid in diabetic and nondiabetic peritoneal dialysis patients[J]. Adv Perit Dial, 2015, 31: 11-16.
[29]
Wallace AM,McMahon AD,Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS)[J]. Circulation, 2001, 104(25): 3052-3056.
[30]
Kim DJ,Oh DJ,Kim B, et al. The effect of continuous ambulatory peritoneal dialysis on change in serum leptin[J]. Perit Dial Int, 1999, 19(Suppl 2): S172-S175.
[31]
Teta D,Tedjani A,Burnier M, et al. Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes[J]. Nephrol Dial Transplant, 2005, 20(7): 1329-1335.
[32]
Moberly JB,Mujais S,Gehr T, et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients[J]. Kidney Int Suppl, 2002, 81: S23-S33.
[33]
Furuya R,Odamaki M,Kumagai H, et al. Beneficial effects of icodextrin on plasma levels of adipocytokines in peritoneal dialysis patients[J]. Nephrol Dial Transplant, 2006, 21(2): 494-498.
[34]
Little J,Phillips I,Russel I, et al. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factor[J]. J Am Soc Nephrol, 1998, 9(10): 1931-1939.
[35]
Li PK,Culleton BF,Ariza A, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients[J]. J Am Soc Nephrol, 2013, 24(11): 1889-1900.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[3] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[10] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[13] 吴天宇, 刘子璇, 杨浦鑫, 贾思明, 丁凯, 程晓东, 李泳龙, 陈伟, 吕红芝, 张奇. 腰椎间盘突出症保守治疗进展[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 379-384.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?